Protocol and baseline data for a multi-year cohort study of the effects of different mass drug treatment approaches on functional morbidities from schistosomiasis in four African countries
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Protocol and baseline data for a multi-year cohort study of the effects of different mass drug treatment approaches on functional morbidities from schistosomiasis in four African countries. / Shen, Ye; King, Charles H.; Binder, Sue; Zhang, Feng; Whalen, Christopher C.; Secor, W. Evan; Montgomery, Susan P.; Mwinzi, Pauline N. M.; Olsen, Annette; Magnussen, Pascal; Kinung'hi, Safari; Phillips, Anna E.; Nala, Rassul; Ferro, Josefo; Aurelio, H. Osvaldo; Fleming, Fiona; Garba, Amadou; Hamidou, Amina; Fenwick, Alan; Campbell, Carl H., Jr.; Colley, Daniel G.
I: B M C Infectious Diseases, Bind 17, 652, 2017.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Protocol and baseline data for a multi-year cohort study of the effects of different mass drug treatment approaches on functional morbidities from schistosomiasis in four African countries
AU - Shen, Ye
AU - King, Charles H.
AU - Binder, Sue
AU - Zhang, Feng
AU - Whalen, Christopher C.
AU - Secor, W. Evan
AU - Montgomery, Susan P.
AU - Mwinzi, Pauline N. M.
AU - Olsen, Annette
AU - Magnussen, Pascal
AU - Kinung'hi, Safari
AU - Phillips, Anna E.
AU - Nala, Rassul
AU - Ferro, Josefo
AU - Aurelio, H. Osvaldo
AU - Fleming, Fiona
AU - Garba, Amadou
AU - Hamidou, Amina
AU - Fenwick, Alan
AU - Campbell, Carl H., Jr.
AU - Colley, Daniel G.
PY - 2017
Y1 - 2017
N2 - BackgroundThe Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) focus is on randomized trials of different approaches to mass drug administration (MDA) in endemic countries in Africa. Because their studies provided an opportunity to evaluate the effects of mass treatment on Schistosoma-associated morbidity, nested cohort studies were developed within SCORE’s intervention trials to monitor changes in a suite of schistosomiasis disease outcomes. This paper describes the process SCORE used to select markers for prospective monitoring and the baseline prevalence of these morbidities in four parallel cohort studies.MethodsIn July 2009, SCORE hosted a discussion of the potential impact of MDA on morbidities due to Schistosoma infection that might be measured in the context of multi-year control. Candidate markers were reviewed and selected for study implementation. Baseline data were then collected from cohorts of children in four country studies: two in high endemic S. mansoni sites (Kenya and Tanzania), and two in high endemic S. haematobium sites (Niger and Mozambique), these cohorts to be followed prospectively over 5 years.ResultsAt baseline, 62% of children in the S. mansoni sites had detectable eggs in their stool, and 10% had heavy infections (≥ 400 eggs/g feces). Heavy S. mansoni infections were found to be associated with increased baseline risk of anemia, although children with moderate or heavy intensity infections had lower risk of physical wasting. Prevalence of egg-positive infection in the combined S. haematobium cohorts was 27%, with 5% of individuals having heavy infection (≥50 eggs/10 mL urine). At baseline, light intensity S. haematobium infection was associated with anemia and with lower scores in the social domain of health-related quality-of-life (HRQoL) assessed by Pediatric Quality of Life Inventory.ConclusionsOur consensus on practical markers of Schistosoma-associated morbidity indicated that height, weight, hemoglobin, exercise tolerance, HRQoL, and ultrasound abnormalities could be used as reference points for gauging treatment impact. Data collected over five years of program implementation will provide guidance for future evaluation of morbidity control in areas endemic for schistosomiasis.
AB - BackgroundThe Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) focus is on randomized trials of different approaches to mass drug administration (MDA) in endemic countries in Africa. Because their studies provided an opportunity to evaluate the effects of mass treatment on Schistosoma-associated morbidity, nested cohort studies were developed within SCORE’s intervention trials to monitor changes in a suite of schistosomiasis disease outcomes. This paper describes the process SCORE used to select markers for prospective monitoring and the baseline prevalence of these morbidities in four parallel cohort studies.MethodsIn July 2009, SCORE hosted a discussion of the potential impact of MDA on morbidities due to Schistosoma infection that might be measured in the context of multi-year control. Candidate markers were reviewed and selected for study implementation. Baseline data were then collected from cohorts of children in four country studies: two in high endemic S. mansoni sites (Kenya and Tanzania), and two in high endemic S. haematobium sites (Niger and Mozambique), these cohorts to be followed prospectively over 5 years.ResultsAt baseline, 62% of children in the S. mansoni sites had detectable eggs in their stool, and 10% had heavy infections (≥ 400 eggs/g feces). Heavy S. mansoni infections were found to be associated with increased baseline risk of anemia, although children with moderate or heavy intensity infections had lower risk of physical wasting. Prevalence of egg-positive infection in the combined S. haematobium cohorts was 27%, with 5% of individuals having heavy infection (≥50 eggs/10 mL urine). At baseline, light intensity S. haematobium infection was associated with anemia and with lower scores in the social domain of health-related quality-of-life (HRQoL) assessed by Pediatric Quality of Life Inventory.ConclusionsOur consensus on practical markers of Schistosoma-associated morbidity indicated that height, weight, hemoglobin, exercise tolerance, HRQoL, and ultrasound abnormalities could be used as reference points for gauging treatment impact. Data collected over five years of program implementation will provide guidance for future evaluation of morbidity control in areas endemic for schistosomiasis.
KW - Schistosomiasis
KW - Schistosoma haematobium
KW - Schistosoma mansoni
KW - Morbidity
KW - Drug therapy
KW - Praziquantel
KW - Africa
KW - Cohort study
KW - Kenya
KW - Mozambique
KW - Niger
KW - Tanzania
U2 - 10.1186/s12879-017-2738-5
DO - 10.1186/s12879-017-2738-5
M3 - Journal article
C2 - 28962552
VL - 17
JO - B M C Infectious Diseases
JF - B M C Infectious Diseases
SN - 1471-2334
M1 - 652
ER -
ID: 184766803